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Abstract
Rationale Thyroid hormones and their interactions with cate-
cholamines play a potentially important role in alterations of
mood and cognition.
Objectives This study aimed to examine the neurobiological
effects of catecholamine depletion on thyroid hormones by
measuring endocrine and cerebral metabolic function in
unmedicated subjects with remitted major depressive disorder
(RMDD) and in healthy controls.
Methods This was a randomized, placebo-controlled, and
double-blind crossover trial that included 15 unmedicated
RMDD subjects and 13 healthy control subjects. The partic-
ipants underwent two 3-day-long sessions at 1-week intervals;
each participant was randomly administered oral α-methyl-
para-tyrosine in one session (catecholamine depletion) and an
identical capsule containing hydrous lactose (sham depletion)
in the other session prior to a [18F]-fluorodeoxyglucose posi-
tron emission tomography scan.
Results Serum concentrations of free T3 (FT3), free T4 (FT4),
and TSH were obtained and assessed with respect to their
relationship to regional cerebral glucosemetabolism. Both serum
FT3 (P =0.002) and FT4 (P =0.0009) levels were less
suppressed after catecholamine depletion comparedwith placebo
treatment in the entire study sample. There was a positive asso-
ciation between both FT3 (P=0.0005) and FT4 (P=0.002) and
depressive symptoms measured using the Montgomery–Åsberg
Depression Rating Scale. The relative elevation in FT3 level was
correlated with a decrease in regional glucose metabolism in the
right dorsolateral prefrontal cortex (rDLPFC; P <0.05,
corrected).
Conclusions This study provided evidence of an association
between a thyroid–catecholamine interaction and mood regu-
lation in the rDLPFC.
Keywords Triiodothyronine . PET . Thyroid . Depression .
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Introduction
The association between thyroid function, brain metabolism,
and mood has drawn increasing attention in recent years within
the clinical neuroscience literature. With improvements in neu-
roimaging techniques, some insights have been gained into the
effects of thyroid hormones on the central nervous system, and
it is now well established that these hormones modulate a
variety of cerebral functions that are involved in mood and
cognition (Bauer et al. 2008). Notably, research suggests that
mood disorders, cognitive impairment, and other psychiatric
symptoms may arise even in subjects with subclinically dis-
turbed thyroid function (Zhu et al. 2006). Patients with manifest
thyroid disorders have been shown to have a higher disposition
to the development of depressive symptoms (Hendrick et al.
1998), including anxiety induced by hyperthyroidism (Kathol
and Delahunt 1986). Conversely, depression may be accompa-
nied by various subtle thyroid abnormalities. Relatively few
previous functional neuroimaging studies have investigated the
neural correlates of mood dysfunction in patients with hypo-
thyroidism (Bauer et al. 2009; Constant et al. 2001; Nagamachi
et al. 2004; Schraml et al. 2006; Zhu et al. 2006), and these
studies reported cerebral hypoperfusion as the most consistent
finding (Bauer et al. 2009; Constant et al. 2001; Forchetti et al.
1997; Kinuya et al. 1999; Krausz et al. 2007, 2004; Nagamachi
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et al. 2004; Schraml et al. 2006). In a subgroup of patients, this
hypoperfusion subsided after thyroid replacement therapy
(Bauer et al. 2009). Thus, the mechanisms underlying the
interactions between thyroid function, brain metabolism, and
mood remain to be clarified.
The study of the interactions between thyroid hormones
and catecholamines is a promising approach to the elucidation
of the relationship between central thyroid function and mood.
The clinical symptoms of sympathetic overactivity and hyper-
thyroidism are strikingly similar, and the similarities between
the physiological effects of thyroid hormones and catechol-
amines suggest interactions at both peripheral and central
receptor sites (Harrison 1964; Waldstein 1966). At the latter
sites, such interactions might explain the augmentation effects
of thyroid hormones in patients with major depressive disor-
der (MDD) who are treated with monoaminergic antidepres-
sants (Bauer and Whybrow 2001).
The experimental paradigm of catecholamine depletion
affords a relatively direct way to investigate thyroid–catechol-
amine interactions in humans (Hasler et al. 2008). This con-
dition can be induced by administering α-methyl-para-tyro-
sine (AMPT), which is a competitive inhibitor of the rate-
limiting enzyme in catecholamine synthesis, tyrosine hydrox-
ylase (Nagatsu et al. 1964), and decreases catecholamine
transmission by depleting central dopamine and norepineph-
rine stores (Stine et al. 1997; Verhoeff et al. 2003). We have
reported previously that decreased catecholaminergic neuro-
transmission was associated with increased depressive and
anhedonic symptoms and with elevated activity in the lim-
bic–cortical–striatal–pallidal–thalamic circuitry (Hasler et al.
2008). Here, we examined the same study population with
respect to the neurobiological effects of catecholamine deple-
tion on thyroid hormones. To avoid a medication bias, we
studied unmedicated subjects with remitted MDD (RMDD)
and healthy controls to measure endocrine and cerebral met-
abolic function. We used the free T3 (FT3), free T4 (FT4), and
TSH serum concentrations and the [18F]-fluorodeoxyglucose
(18FDG) positron emission tomography (PET) technique to
assess the relationships between neurochemistry, neurophysi-
ology, and the level of depression measured using the
Montgomery–Åsberg Depression Rating Scale (MADRS).
Because of the conflicting results regarding the relationship
between thyroid hormones and depression (Joffe 1993), we
based our hypotheses on relatively solid endocrinological data
linking catecholamines to thyroid hormones. Since dopami-
nergic transmission inhibits TSH secretion (Kaptein et al.
1980), and catecholamines block the TSH-induced stimula-
tion of thyroid cells in vitro (Maayan 1990; Oda et al. 1991),
we hypothesized that catecholamine depletion results in
higher serum TSH and thyroid hormone levels compared with
placebo treatment. In addition, we expected that even small
effects of catecholamine depletion on thyroid hormones, with-
in the euthyroid state, would suffice to induce clinically
relevant mood effects since the brain seems to be sensitive
to small changes in thyroid hormone levels (Joffe 1993;
Meyer and Hesch 1983; Schueler et al. 1990; Yamada and
Wilber 1990). Given that only a few imaging findings are
available that have linked thyroid hormones and brain metab-
olism, and given that these findings were derived from pa-
tients with hypothyroidism who often showed depressive
symptoms as a side effect of their illness rather than from
patients with true MDD, any hypothesis formulated on the
relationship between thyroid hormones, catecholamines, and
brain metabolism in patients with remitted MDD may at best
be viewed as preliminary. As the cerebral AMPT main effect
was an increase in metabolism in the bilateral anteroventral
striatum (AVS) (Hasler et al. 2008), we hypothesized that this
region of interest (ROI) is associated with alterations in thy-
roid hormone levels. Given the wide distribution of catechol-
aminergic systems and thyroid hormone receptors throughout
the brain (Ruel et al. 1985; Schwartz and Oppenheimer 1978),
and furthermore, given that thyroid hormones appear to reg-
ulate central noradrenergic neurotransmission with T3 possi-
bly acting as a co-transmitter with norepinephrine within the
adrenergic receptor system (Gordon et al. 1999), we applied
an additional whole-brain analysis in an exploratory fashion.
Experimental procedures
Participants
We used the data from the study sample that was described in
previous studies (Hasler et al. 2008, 2009; Meyers et al. 2011).
The experimental group comprised individuals who were aged
18–56 years and who met the Diagnostic and Statistical Manual
of Mental Disorders, fourth edition (DSM-IV) criteria for MDD
in full remission (RMDD). The healthy controls had no history
of any psychiatric disorders and nomajor psychiatric disorders in
first-degree relatives. Diagnosis was established by the
Structured Clinical Interview for DSM-IV and confirmed via
an unstructured interview with a psychiatrist. The subjects were
recruited through the outpatient clinical services of the National
Institutes ofMental Health and by advertisements placed in local
newspapers and posters placed on the National Institutes of
Health campus. Exclusion criteria included major medical ill-
nesses, pregnancy, psychotropic drug exposure (including nico-
tine) within the previous 3 months, substance abuse within the
previous year, a lifetime history of substance dependence, psy-
chiatric disorders other than MDD, and structural brain abnor-
malities that were observed using magnetic resonance imaging
(MRI). Inclusion criteria required that RMDD subjects had
remained in remission without medications for at least 3 months
and had manifested an onset of depression before 40 years of
age. Written informed consent was obtained, as approved by the
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institutional review board of the National Institute of Mental
Health.
Experimental design
Using a randomized, double-blind, and placebo-controlled cross-
over design, subjects underwent two identical sessions that were
separated by at least 1week, inwhich they received either a body
weight-adjusted AMPT dose or a placebo (see Hasler et al. 2008
for details). To reduce the risk of adverse reactions, a body
weight-adjusted AMPT dose of 40 mg/kg of body weight was
administered orally, up to a maximum dose of 4 g, over 22 h.
Sham depletion used identical capsules containing hydrous lac-
tose. Each session lasted 3 days and was performed on an
inpatient basis at the National Institutes of Health Clinical
Center. To reduce the risk of crystalluria during AMPT admin-
istration, subjects were given sodium bicarbonate, drank at least
2 L of water daily, and underwent urinalysis twice daily.
Behavioral ratings included the MADRS and the Beck
Anxiety Inventory (BAI). Venous blood was sampled before
and 24, 36, and 48 h after the administration of the first AMPT
dose in each session, to measure serum FT3, FT4, and TSH
levels using an electrochemiluminescent immunoassay
(Boehringer Ingelheim Pharma GmbH & Co., KG, Ingelheim,
Germany).
PET imaging
The PET imaging methods have been described in detail in our
previous report using the same participant cohort (Hasler et al.
2008). Briefly, the PET images were acquired 30 h after the
administration of the first AMPT/placebo dose, which
corresponded to the period when peak behavioral responses
were expected (Berman et al. 1999). Scanning was performed
using the GE Advance scanner in three-dimensional mode (35
contiguous slices, 4.25 mm thickness; three-dimensional reso-
lution=6 mm full width at half maximum; GE Healthcare,
Waukesha, WI, USA) and a slow bolus (over 2 min) injection
of 18FDG. To obviate the need for arterial blood sampling,
cerebral glucose utilization was quantified using a method that
combines the left ventricular chamber time–tissue radioactivity
data that were measured via dynamic PET imaging of the heart
with venous blood sampling, to provide 18FDG input function
(Moore et al. 2003). This method has been validated previously
by comparing it to more invasive approaches that use arterial
plasma sampling (Moore et al. 2003). During image processing,
the left ventricular time–radioactivity curve was extended in
time to include the time of the brain emission scan by obtaining
venous blood samples 25, 30, 35, and 50 min after 18FDG
injection. The mean radioactivity of these samples was divided
by the mean left ventricular radioactivity concentration regis-
tered between 25 and 35 min postinjection. This ratio was used
to scale the 50-min venous sample concentration, which then
was appended to the left ventricular curve to complete the input
function that was used to generate parametric images of the
regional cerebral metabolic rates for glucose (rCMRglu), as
described by Moore and colleagues (2003). To provide an
anatomical framework for the analysis of the PET images,
structural MRI scans were acquired using a 3.0-T scanner.
PET image analysis
To assess the correlations between AMPT-induced thyroid alter-
ations and AMPT-induced metabolic changes across the whole
brain, a voxel-wise analysis of the PET datawas performed using
the MATLAB (MATLAB version 8, release 14; The
MathWorks, Inc., Natick, MA, USA), Statistical Parametric
Mapping 8 (SPM8) (Wellcome Trust Centre for Imaging,
London, England; www.fil.ion.ucl.ac.uk/spm8), and the
toolbox aslm (Homan et al. 2012). PET images were co-
registered to the MR images and spatially normalized to the
Montreal Neurological Institute brain template using SPM8.
Images were filtered with a 6-mm Gaussian smoothing kernel
to compensate for anatomical variability andmisalignment errors
that might have arisen during spatial normalization. The statisti-
cal models that were used to compare the normalized rCMRglu
included the main effects of placebo vs. drug, subject, and the
differences in the serum levels of FT3, FT4, and TSH. To
account for differences in baseline levels, the differences in
thyroid hormone levels were calculated between the third time
point (which coincides approximately with FDG scanning and
the peak depressive responses (Hasler et al. 2008)) and the first
time point (baseline). We reported clusters with a voxel-level
threshold of P <0.05, whole-brain corrected for family-wise
error.
Statistical analyses
Full factorial linear mixed models with restricted maximum
likelihood estimations were used to examine the effects of
various outcome measures. Schwarz's Bayesian criteria were
used to determine the best fitting covariance structure for each
set of measures in cases in which the typical compound sym-
metry approach used by ANOVA did not provide the optimal
structure for the extant data. The effects of drug, diagnosis, and
time on FT3, FT4, and TSH levels were assessed using linear
mixed models with a first-order autoregressive covariance
structure. The effects of treatment, diagnosis, and time on
MADRS and BAI scores were assessed using linear mixed
models with an autoregressive covariance structure.
Additional models of the MADRS scores were calculated to
include FT3, FT4, or TSH levels as additional fixed effects, to
assess the influence of thyroid hormones on depressive symp-
toms. Subject number and treatment sequence were included as
random effects in all models. Post hoc t tests involved the
Tukey correction for multiple comparisons. The significance
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thresholds for these contrasts were set at a two-tailed alpha=
0.05. SAS 9.2 (SAS Institute, Inc., Cary, NC, USA) was used
for all analyses. The means of the data are reported, with their
associated standard deviations.
Results
The clinical and demographic characteristics of the subject
samples are detailed in Table 1.
Behavioral results
Fifteen subjects with RMDD and 13 healthy controls were
included in the study. The 13 healthy volunteers (12 females;
mean age±standard deviation (SD)=39±12 years) were not
significantly different from the 15 RMDD subjects (14 females;
mean age±SD=39±11 years) regarding sex ratio and mean
age. The mean ratings of mood and anxiety symptoms, sleep-
iness, and akathisia for each treatment condition and group, as
well as the course of rebound hypomanic symptoms (which
were classified according to treatment and group), have been
reported previously (Hasler et al. 2008, 2009; Meyers et al.
2011). In addition, serum prolactin levels were increased fol-
lowing catecholamine depletion (F [1, 203]=81.79, P <
0.0001), and no effect of diagnosis (P=0.58) or treatment-by-
diagnosis interaction (P=0.97) was evident. There was no
effect of session order (i.e., whether the AMPT or placebo
session occurred first) on thyroid hormone levels, and no
treatment-by-session interaction was evident, suggesting that
no carry-over effects were present. Consequently, the endocri-
nologic data of both sessions were examined further.
FT3 concentration in serum
Figure 1a shows the mean FT3 serum concentrations (with
standard errors) for the AMPTand placebo treatments. Serum
FT3 levels showed a time effect across both conditions and
groups (F [3, 144]=43.34, P <0.0001) that was attributable to
a suppression at 36 h and a rebound at 48 h. Compared to
placebo, serum FT3 levels were less suppressed after AMPT
administration in both the RMDD and control samples (F [1,
79.5]=10.62, P=0.002). No effect of diagnosis or treatment-
by-diagnosis interaction was evident (P=0.4 and P=0.8, re-
spectively). The mean ΔFT3 levels (differences between
FT3 at t =3 and FT3 at baseline under AMPT treatment minus
the same difference under placebo treatment) were 0.47±0.66
(range, −0.3 to 2.1) and 0.39±0.69 (range, −0.7 to 1.8) in
RMDD patients and controls, respectively (t [26]=−0.29, P=
0.77). To examine the effects of FT3 on depressive symptoms,
FT3 was included as an additional fixed effect in the modeling
of the MADRS and BAI responses. We observed a positive
association between FT3 levels and depressive symptoms
measured using the MADRS (F [1, 85.5]=12.97, P =
0.0005). No association was found between FT3 levels and
anxiety symptoms measured using the BAI (P=0.28).
FT4 concentration in serum
Figure 1b shows the mean FT4 serum concentrations (with
standard errors) for the AMPT and placebo treatments. Serum
FT4 levels showed a time effect (F [3, 149]=12.61, P <
0.0001) that was attributable to a suppression at 36 h and a
rebound at 48 h. Compared to placebo, serum FT4 levels were
less suppressed after AMPT administration in both the RMDD
and control samples (F [1, 66]=12.2, P=0.0009). No diagno-
sis effect (P=0.3) or treatment-by-diagnosis interaction (P=
0.4) was evident. The meanΔFT4 levels (differences between
FT4 at t =3 and FT4 at baseline under AMPT treatment minus
the same difference under placebo treatment) were 0.95±1.02
(range, −0.3 to 2.9) and 1.75±1.35 (range, −0.2 to 4.1) in
RMDD patients and controls, respectively (t [25]=1.76, P=
0.09). To examine the effects of FT4 on depressive symptoms,
FT4 was included as an additional fixed effect in the modeling
of the MADRS and BAI responses. We observed a positive
association between FT4 levels and depressive symptomsmea-
sured using the MADRS (F [1, 57]=9.89, P=0.003). No
association was found between FT4 levels and anxiety symp-
toms measured using the BAI (P=0.66).
TSH concentration in serum
Figure 1c shows the mean TSH serum concentrations (with
standard errors) for the AMPT and placebo treatments. There
was a time effect in serum TSH concentrations (F [3, 151]=
41.88, P <0.0001) that was attributable to a suppression at
Table 1 Demographic and clinical characteristics of unmedicated sub-
jects with remitted major depressive disorder (RMDD) and healthy
controls
Characteristic RMDD
(n =15)
Controls
(n =13)
Sex, no. f/m 14/1 12/1
Age, mean (SD), years 39 (11) 39 (12)
Age at onset, mean (SD), years 24 (8.3) NA
Past major depressive episodes, mean (SD), no. 2.7 (1.4) 0
Time in remission, months
Mean (SD) 35 (28) NA
Range 7–18 NA
First-degree relative(s) with a mood disorder, no. 14 0
Remote (>1 year ago) history of alcohol abuse, no. 3 1
History of drug abuse, no. 0 0
MADRS score at study entry, mean (SD) 2.3 (2.1) 0.5 (1.2)
f/m female/male, MADRS Montgomery–Åsberg Depression Rating
Scale, NA not applicable, SD standard deviation
412 Psychopharmacology (2014) 231:409–417
36 h and a rebound at 48 h across groups and conditions.
Catecholamine depletion had no treatment effect (P=0.4) and
no diagnosis effect (P=0.8) on serum TSH concentrations.
Further, no treatment-by-diagnosis interaction was evident
(P=0.7). There was no association between TSH levels and
depressive symptoms measured using the MADRS (P=0.5)
or anxiety symptoms measured using the BAI (P=0.43).
Correlations between regional cerebral metabolism
and thyroid hormone serum concentration
Whole-brain metabolism did not differ significantly between
the groups at baseline or between the placebo and AMPT
conditions (P >0.25 for the main effect of group, the main
effect of treatment, and group-by-treatment interactions).
Thus, the analyses were performed using globally normalized
data, to reduce the variability that was introduced by nonspecific
fluctuations in whole-brain activity. In addition, in the absence
of effects of diagnosis and treatment-by-diagnosis on FT3,
FT4, and TSH levels, we pooled the data of both groups to
perform the analysis. The ROI analysis showed that the
AMPT-induced elevation in brain metabolism in the AVS
did not correlate with the relative elevation in serum FT3
levels (P=0.33). The additional whole-brain analysis revealed
that changes in serum FT3 levels correlated negatively with
metabolic changes in the right inferior frontal gyrus
(Brodmann area 46), which is part of the right dorsolateral
prefrontal cortex (rDLPFC; peak coordinates x , y, and z , 54,
28, and 12; cluster size, 102 voxels; t=6.25, P<0.05, whole-
brain corrected for family-wise error; Fig. 2). No other cluster
in the brain survived a correction for family-wise error, and
no regions were identified that exhibited positive correlations
between metabolic changes and changes in serum FT3 levels.
In addition, a correlational analysis using serum FT4 or TSH
a
c
b
Fig. 1 Mean free T3 (FT3, a), mean free T4 (FT4, b), and mean TSH
(c) levels with standard errors in healthy control subjects and subjects
with remitted major depressive disorder (RMDD) during the course of the
catecholamine depletion study using alpha-methyl-para -tyrosine
(AMPT) and placebo treatments. Serum thyroid hormone levels at the
third time point, which coincides approximately with fluorodeoxyglucose
scanning and with peak depressive responses (Hasler et al. 2008), were
used in the additional correlational analysis of cerebral glucose metabo-
lism. *P<0.05, indicating a significant treatment effect
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level changes as covariates did not reveal any significant
regions after applying corrections for multiple testing.
Discussion
This study compared the effects of catecholamine depletion on
thyroid hormones and brain metabolism. The serum FT3 and
FT4 concentrations were higher after catecholamine depletion
than theywere after placebo treatment in subjects with RMDD
and in healthy controls. A significant correlation between an
AMPT-induced relative elevation of FT3 level and a corre-
sponding decrease in brain metabolism was found in the
rDLPFC. There was a positive association between both se-
rum FT3 and FT4 levels and depressive symptoms measured
using the MADRS.
Regardless of treatment, we observed a suppression of
TSH, FT3, and FT4 serum levels at 36 h and a rebound at
48 h which is difficult to interpret. Possibly, the stress of the
study procedures (blood drawing, lying in the scanner) has
contributed to this hormone suppression. We used catechol-
amine depletion with AMPT to study the well-known rela-
tionship between thyroid hormones and the sympathetic
nervous system function (Harrison 1964). Hyperthyroidism
bears a resemblance to sympathetic overactivity because of
the physiological effects that are shared by thyroid hormones
and catecholamines. In addition, they interact synergistically,
and the effects of catecholamines are exaggerated by excess
thyroid hormones and attenuated by thyroid hormone defi-
ciencies (Waldstein 1966). Therefore, catecholamine deple-
tion was previously considered a possible therapy for hyper-
thyroidism (Canary et al. 1957), before it was found that it
caused a high incidence of mental depression as a side effect
(Buchanan et al. 1959). Consistent with our a priori hypothe-
sis, serum FT3 and FT4 levels were less suppressed under
AMPT than they were under placebo treatment in the whole
sample. Previous research has suggested that catecholamines
block the TSH-induced stimulation of thyroid cells in vitro
(Maayan 1990; Oda et al. 1991). Thus, the relative elevations
in FT3 and FT4 levels observed might be attributable to
decreased catecholaminergic neurotransmission.
Our finding that serum FT3 and FT4 levels were less
suppressed under AMPT is consistent with the hypothesis
linking thyroid hormones and depressive symptoms. This
hypothesis was first proposed by Bauer and Whybrow
(1988) and suggests that the increased FT4 measures in
Fig. 2 Statistical Parametric Mapping image sections illustrating areas in
which AMPT-induced changes in FT3 levels correlated with correspond-
ing changes in regional glucose metabolism in a voxel-wise analysis of
the combined subject sample (n=28). The serum FT3 levels for each
subject were calculated as the difference in the baseline-corrected levels
measured at the third time point (which coincides approximately with
fluorodeoxyglucose scanning and with peak depressive responses; Hasler
et al. 2008) between the drug and placebo conditions. This reflected the
magnitude of the FT3 alterations that were induced by catecholamine
depletion. The statistical models used to assess changes in normalized
regional cerebral metabolic rates for glucose included the main effect of
drug vs. placebo, the main effect of the serum FT3 levels, and the main
effect of subject. There was a significant negative relationship in the right
inferior frontal gyrus (Brodmann area 46), which is part of the right
dorsolateral prefrontal cortex (peak coordinates x , y, and z , 54, 28, and
12; cluster size, 102 voxels; t=6.25, P <0.05, whole-brain corrected for
family-wise error). No region was identified in which the changes in
metabolism correlated positively with the changes in serum FT3 levels.
Voxels are displayed on orthogonal planes that were determined from an
anatomical MR brain image. The figures are depicted in neurological
orientation. The gray-scale image is a T1 structural MR image that is a
representative ofMontreal Neurological Institute space. Positive values of
the x , y, and z coordinates approximately represent millimeters to the
right, anterior, and superior direction relative to the anterior commissure.
The colored bar indicates voxel t values. Next to the brain slices, the
changes in regional metabolism are plotted against the changes in serum
FT3 levels. There was a negative relationship between AMPT-induced
changes in normalized regional/global cerebral metabolic rates for glu-
cose and the corresponding changes in serum FT3 levels (r =−0.78, P<
0.001). The regression line (determined from the Pearson correlation
coefficient) represents the regression of the data from RMDD and control
subjects pooled together (n=28)
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depression are a compensatory response “to maintain affective
homeostasis” (Joffe 1993). This assumption is consistent with
the fact that clinical hypothyroidism is associated with depres-
sive symptoms that subside with thyroid replacement therapy
(Hendrick et al. 1998) and is further supported by the obser-
vation that thyroid hormones have proven to be useful as
augmentative or accelerating treatments in affective disorders
(Bauer et al. 2002). The efficacy of both T3 and T4 has been
assessed in the treatment of MDD. The majority of studies
have assessed the efficacy of T3, and an effect on both the
acceleration and the augmentation of mostly tricyclic antide-
pressants by T3 has been shown (Altshuler et al. 2001;
Aronson et al. 1996). A smaller number of studies have
examined the use of T4 and found that the augmentation of
antidepressant therapy by T4 in supraphysiological doses is
effective in roughly 50 % of patients with treatment-resistant
depression (Bauer et al. 2005). Comparatively, a significantly
higher response to tricyclic antidepressants has been found for
T3 (53 %) vs. T4 (19 %) (Joffe and Singer 1990). However,
the latter study used low T4 doses, whereas more recent
studies used supraphysiological doses (Bauer et al. 2005).
Thus, the relatively elevated levels of FT3 and FT4 found in
our study support the hypothesis of a compensatory response;
this finding is in line with that of an early report that suggested
a catecholamine–thyroid interaction in the central nervous
system (Whybrow and Prange 1981). This compensatory
hypothesis is extended by the suggestion that thyroid hor-
mones compensate for central catecholamine deficiency.
This extended hypothesis is plausible, given that central cat-
echolamines are modulated by thyroid hormones. The rela-
tively elevated serum FT4 and FT3 levels observed could then
be viewed as an insufficient effort to compensate for the
decrease in catecholamine levels. This is further supported
by our finding of an association between subtle alterations in
FT3 levels and altered regional brain metabolism.
Specifically, the relatively elevated FT3 levels observed after
catecholamine depletion were negatively correlated with a
change in regional cerebral metabolism in the rDLPFC. The
rDLPFC has been implicated in the pathogenesis of depres-
sive symptoms based on various types of evidence (Mayberg
2003). There is reasonable evidence to suggest that glucose
metabolism in the rDLPFC is increased in patients with MDD
(Mayberg 2003), which may explain why many patients with
depression benefit from the inhibitory effect of low-frequency
transcranial magnetic stimulation (TMS) in this region
(Gershon et al. 2003), even though the most widely used
TMS target region is slightly superior to the cluster identified
here. Thus, our findings support the suggested involvement of
the rDLPFC in the pathogenesis of depressive symptoms and
lend to previous results by linking decreased regional glucose
metabolism to relatively elevated serum FT3 levels. The de-
crease in regional metabolism might then be considered a
compensatory response to the depressive symptoms related
to catecholamine deficiency. However, since we did not find a
difference between subjects with RMDD and controls regard-
ing AMPT-induced changes in serum FT3 levels and corre-
sponding changes in regional glucose metabolism in the
rDLPFC, this finding does not seem to be specific to MDD.
Another hypothesis, conflicting to the first hypothesis and
in contrast to our finding, has linked depressive symptoms to
an overactive thyroid axis. Most consistently, higher mean
FT4 levels have been reported in patients with MDD than in
subjects with RMDD and healthy controls (Joffe 2006); more-
over, these levels subsided with effective treatment (Joffe et al.
1996). These increased FT4 levels might contribute to depres-
sive symptoms by inducing higher levels of anxiety, as in
hyperthyroidism (Kathol and Delahunt 1986). Thus, it has
been hypothesized that the thyroid axis is overactive in
MDD (Joffe and Sokolov 1994). However, our finding of an
association between AMPT-induced depressive symptoms
and AMPT-induced relative elevations in thyroid hormone
levels was not mediated by a thyroid hormone-related increase
in anxiety because we failed to find any association between
thyroid hormones and anxiety symptoms.
In contrast with our a priori hypothesis, there was no
association between FT3 levels and altered metabolism in
the AVS, which was the main cerebral AMPT effect reported
previously (Hasler et al. 2008). This finding is consistent with
the results of our previous study, which did not find a direct
relationship between a RMDD diagnosis or AMPT-induced
depressive symptoms and AVS metabolism (Hasler et al.
2008). Although, in our previous study, we found that the
strongest relationship between catecholamine depletion and
depressive symptoms was present in the thalamus and the
ventromedial prefrontal cortex, the results of the present study
suggest that the thyroid–catecholamine interaction that was
associated with mood regulation is located in the rDLPFC.
Surprisingly, AMPT did not affect serum TSH levels sig-
nificantly. Earlier findings have shown that dopaminergic
transmission inhibits TSH secretion (Kaptein et al. 1980),
and later studies have found that AMPT can either cause an
increase (Plosker et al. 1995) or a decrease in TSH levels,
depending on the length of administration (Zimmermann et al.
2001). It is possible, however, that an increase in TSH in
response to catecholamine depletion was offset by a concom-
itant reduction in TSH release resulting from the negative
feedback inhibition that was elicited in response to a relative
elevation in FT3 and FT4 levels.
Our study had several limitations. The relatively small
sample of subjects, the oversampling of female study partic-
ipants, and the ability of RMDD subjects to remain in remis-
sion without current treatment reduced the generalizability of
the results. In addition, we were unable to investigate whether
the catecholamine depletion-induced effects on FT3 and FT4
levels were mediated via peripheral or central receptor effects;
consequently, our study did not establish the mechanism via
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which catecholamine depletion leads to an increase in hor-
mone levels. Moreover, we did not measure plasma or urinary
catecholamine levels to monitor the effect of catecholamine
depletion, because there is no consistent relationship between
central and peripheral catecholamine levels. Instead, we esti-
mated the central AMPT effect by measuring serum prolactin
levels, which is the standard method for assessing the depth of
central catecholamine depletion (Hasler et al. 2008, 2009;
Meyers et al. 2011). In addition, it is possible that the relative
elevation in serum FT3 levels could be due to increased T3
production by conversion of T4 to T3 in various peripheral
organs, given that catecholamines have been shown to mod-
ulate the monodeiodination of T4 to the biologically more
active T3, and that AMPT can alter this process (Ramadan
et al. 2011; Silva and Larsen 1983). Finally, the AMPT effect
on serum FT3 and FT4 levels was relatively subtle, and all
subjects remained euthyroid during the study. Thus, one might
question the clinical significance of these findings. However,
it has to be considered that physiological doses of thyroid
hormones suffice to supplement the effects of antidepressants,
suggesting that even subtle thyroid alterations within the
euthyroid state are compatible with clinically relevant mood
alterations.
In conclusion, this study provided evidence of an associa-
tion between a thyroid–catecholamine interaction and mood
regulation in the rDLPFC.
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